Sri Harsha Chakrapani is a process engineer focused on oral solid dosage validation, cleaning validation, pharmaceutical manufacturing risk, and quality systems. His work focuses on connecting validation lifecycle activities with practical manufacturing performance, batch-release reliability, and operational resilience.

Sri Harsha Chakrapani

Close up of white round tablets on white background. | Image Credit: ©uduhunt -stock.adobe.com

Organizations sometimes treat validation as a document trail that follows manufacturing. In oral solid dosage (OSD) operations, that view is too narrow. A batch record, protocol, or report may be the visible artifact, but the real purpose of validation is to show that the process is understood, controlled, and capable of routine performance within a defined operating space.

That distinction matters in commercial manufacturing. Tablets and capsules move through linked operations, such as dispensing, blending, granulation when applicable, drying, milling, lubrication, compression, coating, packaging, and cleaning between campaigns. A weakness in 1 part of the chain rarely stays isolated. It can become a deviation, laboratory investigation, batch hold, repeat cleaning event, or change-control question. In that sense, validation helps keep the manufacturing system stable.

The FDA’s lifecycle approach to process validation places process design, process qualification, and continued process verification into 1 connected model.

 In site language, validation should not end when the process performance qualification (PPQ) report is approved. PPQ provides evidence at a point in time. Routine production then tests whether the control strategy remains effective under normal variation in materials, operators, equipment condition, cleaning cycles, and schedule.

The business consequence of weak validation is often indirect (

). A process may not immediately fail a specification. Instead, the site may see longer investigations, more conditional batch dispositions, slower quality assurance (QA) review, or repeated technical discussions that do not resolve the underlying issue. These burdens consume manufacturing capacity and reduce confidence in the production plan.

Figure 1. Validation signals across the commercial oral solid dosage lifecycle. (Figure courtesy of the author)

How OSD Processes Create Downstream Disruption

OSD processes are especially sensitive to accumulated variation. Raw-material attributes can affect blend uniformity or granule behavior. Drying can influence residual moisture, flow, compression performance, and dissolution. Milling can change particle-size distribution. Lubrication can affect hardness, friability, and dissolution. Compression can influence weight, thickness, hardness, capping, sticking, and content uniformity. Coating can affect appearance, weight gain, stability, and release characteristics.

Manufacturing and validation teams are familiar with these examples, but they are not always translated into continuity risk. If the validation package does not explain which parameters matter, why limits were selected, and how routine monitoring should respond to adverse trends, the site has a weaker basis for decisions under pressure. During demand increases, campaign changes, equipment problems, or material variability events, that weakness becomes more visible.

Public Examples that Illustrate the Continuity Risk

Public regulatory records show why this point is practical rather than theoretical. FDA’s OSD inspection guide notes that production-scale validation problems have included dissolution, content uniformity, and potency issues.

 In commercial operations, those issues can affect batch disposition, release timing, inventory confidence, and supply planning.

A FDA warning letter involving potassium chloride extended-release capsules described several dissolution failures and questioned whether the company had sufficiently evaluated process changes and API-related explanations.

 The useful lesson is not company-specific: dissolution performance can connect formulation behavior, material attributes, process changes, investigation quality, and continuity of supply.

Cleaning validation provides a second public example. FDA warning letters have cited inadequate cleaning validation or verification on non-dedicated equipment, including residue and cross-contamination concerns.

 In shared-equipment OSD environments, that weakness can remove equipment from service, delay campaigns, increase laboratory workload, and reduce scheduling flexibility (

). Used carefully, public examples reinforce that validation gaps can become continuity risks when technical uncertainty reaches routine manufacturing.

Table 1. Examples of Weak Validation Signals and Potential Continuity Consequences

Cleaning Validation and Capacity Protection

Cleaning validation is correctly grounded in patient safety, current good manufacturing practice (CGMP) expectations, and contamination control.

 Residue limits, sampling locations, recovery studies, visual inspection, analytical method suitability, and dirty and clean hold times must be scientifically justified. At the same time, cleaning validation also affects capacity. Commercial OSD facilities depend on predictable changeovers. When cleaning is uncertain, equipment is not reliably available for the next product or strength.

A recurring cleaning issue can delay campaign starts, increase laboratory workload, force repeat cleaning, and consume QA and manufacturing time. It may also limit flexibility when the schedule changes. A strong cleaning-validation program therefore supports both product quality and operational predictability. The point is not to treat cleaning validation as a scheduling tool; it is that scientifically sound cleaning controls help protect the schedule from avoidable uncertainty.

Continued Process Verification as an Early Warning System

Continued process verification (CPV) is 1 of the most practical links between validation and business continuity. In many organizations, CPV can become a periodic reporting exercise. The more useful approach is to treat CPV as a technical review of whether the process remains in control. For OSD products, useful signals may include assay, content uniformity, dissolution, tablet weight, hardness, thickness, friability, compression force, coating weight gain, yield, and recurring deviation themes.

The value of CPV is not that it produces charts. The value is earlier visibility. A small drift in compression behavior, a recurring moisture-related trend, or a slow change in dissolution performance is easier to manage when detected early. If the pattern is discovered only after multiple deviations or a rejected batch, the site has lost time, capacity, and options. CPV, when reviewed with process knowledge and quality risk management principles, helps technical teams act before the problem becomes repetitive.

Deviation management is another place where the validated state can either be protected or slowly weakened. A deviation investigation that closes with a narrow correction may satisfy an immediate procedural need, but it may not explain the technical cause. If similar deviations continue to appear, the site should question whether the process understanding, control strategy, cleaning approach, or training model is sufficient.

Change control has the same role. Supplier changes, equipment modifications, formulation adjustments, cleaning-procedure updates, analytical-method changes, and process-parameter revisions can all affect the validated state. A strong change-control process does more than ask whether a document must be revised. It asks whether process knowledge supports the change and whether additional validation, verification, monitoring, or risk assessment is required. This is consistent with the broader pharmaceutical quality-system expectation that knowledge and risk management should support lifecycle control.

Managing Validation as an Operating Signal

For site leadership, validation-related metrics should be viewed alongside operational metrics as part of a broader quality-system approach.

 Recurring deviations, repeat cleaning failures, late CPV reviews, unresolved adverse trends, long investigation cycle times, and unplanned batch holds are not simply compliance indicators. They are signals about the health of the manufacturing system.

This does not mean validation should be managed as a finance function. It means manufacturing, QA, technical operations, engineering, laboratory, regulatory, and supply chain teams should understand validation as a shared control system. The same validated state that supports inspection readiness also supports batch release, equipment availability, schedule reliability, and patient supply (

Table 2. Validation Lifecycle Elements and Business-Continuity Value

The Value of Disciplined Process Knowledge Validation

OSD validation should not be reduced to a successful PPQ campaign or a completed report. Those outputs matter, but they are only part of the lifecycle. The larger value is the disciplined process knowledge validation creates and maintains.

A process that is understood, controlled, monitored, and supported by effective deviation and change management is better positioned to keep working under routine commercial conditions. Public regulatory examples involving dissolution problems and cleaning validation weaknesses reinforce the same point: validation gaps do not remain inside the validation file. They can affect investigations, release, equipment availability, and supply reliability. That is why validation is also part of business continuity in commercial OSD manufacturing.

Process Validation: General Principles and Practices. Guidance for Industry.

Oral Solid Dosage Forms Pre/Post Approval Issues. Inspection Guide. FDA. January 1994.

Glenmark Pharmaceuticals Limited, Warning Letter 708270. FDA. July 11, 2025.

KVK-Tech, Inc., Warning Letter 608236. FDA. October 8, 2020.

Mylan Pharmaceuticals, Inc., Warning Letter 557903. FDA. November 9, 2018.

21 CFR Parts 210 and 211, Current Good Manufacturing Practice for Finished Pharmaceuticals.

Quality Systems Approach to Pharmaceutical CGMP Regulations. Guidance for Industry

Articles

Validation in commercial OSD manufacturing is a lifecycle control system—not merely a PPQ report—demonstrating process understanding, robustness, and capability within a defined operating space. Because dispensing through packaging are tightly coupled, unaddressed parameter uncertainty propagates into deviations, investigations, batch holds, and capacity loss. FDA’s lifecycle model underscores the need for continued process verification (CPV) as early warning for drift in critical quality attributes. Public dissolution and cleaning-validation enforcement examples illustrate how gaps undermine batch release, equipment availability, and supply reliability.

 In commercial tablet or capsule operations, validation helps protect the site’s ability to produce, release, and supply product without repeated disruption. This article discusses validation as a technical control system that supports manufacturing continuity.